-
3
-
-
5644233700
-
Immunopathogenesis of oropharyngeal candidiasis in human immunodeficiency virus infection
-
de Repentigny L, Lewandowski D, Jolicoeur P. Immunopathogenesis of oropharyngeal candidiasis in human immunodeficiency virus infection. Clin Microbiol Rev 2004; 17: 729-59.
-
(2004)
Clin Microbiol Rev
, vol.17
, pp. 729-759
-
-
de Repentigny, L.1
Lewandowski, D.2
Jolicoeur, P.3
-
4
-
-
40349100417
-
Novel insights into disseminated candidiasis: pathogenesis research and clinical experience converge
-
Spellberg B. Novel insights into disseminated candidiasis: pathogenesis research and clinical experience converge. PLoS Pathog 2008; 4: e38.
-
(2008)
PLoS Pathog
, vol.4
-
-
Spellberg, B.1
-
5
-
-
77950215343
-
Candidosis, a new challenge
-
Lopez-Martinez R. Candidosis, a new challenge. Clin Dermatol 2010; 28: 178-84.
-
(2010)
Clin Dermatol
, vol.28
, pp. 178-184
-
-
Lopez-Martinez, R.1
-
7
-
-
0032862342
-
In-vitro antifungal activity of liposomal nystatin in comparison with nystatin, amphotericin B cholesteryl sulphate, liposomal amphotericin B, amphotericin B lipid complex, amphotericin B desoxycholate, fluconazole and itraconazole
-
Carrillo-Munoz AJ, Quindos G, Tur C et al. In-vitro antifungal activity of liposomal nystatin in comparison with nystatin, amphotericin B cholesteryl sulphate, liposomal amphotericin B, amphotericin B lipid complex, amphotericin B desoxycholate, fluconazole and itraconazole. J Antimicrob Chemother 1999; 44: 397-401.
-
(1999)
J Antimicrob Chemother
, vol.44
, pp. 397-401
-
-
Carrillo-Munoz, A.J.1
Quindos, G.2
Tur, C.3
-
8
-
-
84857704675
-
Novel, unifying mechanism for amphotericin B and other polyene drugs: electron affinity, radicals, electron transfer, autoxidation, toxicity, and antifungal action
-
Kovacic P, Cooksy A. Novel, unifying mechanism for amphotericin B and other polyene drugs: electron affinity, radicals, electron transfer, autoxidation, toxicity, and antifungal action. Med Chem Commun 2012; 3: 274-80.
-
(2012)
Med Chem Commun
, vol.3
, pp. 274-280
-
-
Kovacic, P.1
Cooksy, A.2
-
9
-
-
84875503043
-
It only takes one to do many jobs: amphotericin B as antifungal and immunomodulatory drug
-
doi.103389/fmicb.2012.00286.
-
Mesa-Arango AC, Scorzoni L, Zaragoza O. It only takes one to do many jobs: amphotericin B as antifungal and immunomodulatory drug. Front Microbiol 2012; doi:10.3389/fmicb.2012.00286.
-
(2012)
Front Microbiol
-
-
Mesa-Arango, A.C.1
Scorzoni, L.2
Zaragoza, O.3
-
10
-
-
84882612782
-
Ratiopharm. Product Monograph (ratio-Nystatin)
-
Ratiopharm. Product Monograph (ratio-Nystatin). 2001; G50-G5.
-
(2001)
-
-
-
12
-
-
0030927488
-
Oropharyngeal candidiasis in patients with AIDS: randomized comparison of fluconazole versus nystatin oral suspensions
-
Pons V, Greenspan D, Lozada-Nur F et al. Oropharyngeal candidiasis in patients with AIDS: randomized comparison of fluconazole versus nystatin oral suspensions. Clin Infect Dis 1997; 24: 1204-7.
-
(1997)
Clin Infect Dis
, vol.24
, pp. 1204-1207
-
-
Pons, V.1
Greenspan, D.2
Lozada-Nur, F.3
-
13
-
-
36248953162
-
Drug-drug interactions with systemic antifungals in clinical practice
-
Depont F, Vargas F, Dutronc H et al. Drug-drug interactions with systemic antifungals in clinical practice. Pharmacoepidemiol Drug Saf 2007; 16: 1227-33.
-
(2007)
Pharmacoepidemiol Drug Saf
, vol.16
, pp. 1227-1233
-
-
Depont, F.1
Vargas, F.2
Dutronc, H.3
-
14
-
-
0026574215
-
Safety and pharmacokinetics of fluconazole in children with neoplastic diseases
-
Lee JW, Seibel NL, Amantea M et al. Safety and pharmacokinetics of fluconazole in children with neoplastic diseases. J Pediatr 1992; 120: 987-93.
-
(1992)
J Pediatr
, vol.120
, pp. 987-993
-
-
Lee, J.W.1
Seibel, N.L.2
Amantea, M.3
-
15
-
-
76649114370
-
Antifungal drug resistance of oral fungi
-
Niimi M, Firth NA, Cannon RD. Antifungal drug resistance of oral fungi. Odontology 2010; 98: 15-25.
-
(2010)
Odontology
, vol.98
, pp. 15-25
-
-
Niimi, M.1
Firth, N.A.2
Cannon, R.D.3
-
16
-
-
0036125293
-
Heterogeneous mechanisms of azole resistance in Candida albicans clinical isolates from an HIV-infected patient on continuous fluconazole therapy for oropharyngeal candidosis
-
Martinez M, Lopez-Ribot JL, Kirkpatrick WR et al. Heterogeneous mechanisms of azole resistance in Candida albicans clinical isolates from an HIV-infected patient on continuous fluconazole therapy for oropharyngeal candidosis. J Antimicrob Chemother 2002; 49: 515-24.
-
(2002)
J Antimicrob Chemother
, vol.49
, pp. 515-524
-
-
Martinez, M.1
Lopez-Ribot, J.L.2
Kirkpatrick, W.R.3
-
17
-
-
0037453179
-
Formulation of amphotericin B as nanosuspension for oral administration
-
Kayser O, Olbrich C, Yardley V et al. Formulation of amphotericin B as nanosuspension for oral administration. Int J Pharm 2003; 254: 73-5.
-
(2003)
Int J Pharm
, vol.254
, pp. 73-75
-
-
Kayser, O.1
Olbrich, C.2
Yardley, V.3
-
18
-
-
77955274105
-
Delivery of amphotericin B nanosuspensions to the brain and determination of activity against Balamuthia mandrillaris amebas
-
Lemke A, Kiderlen AF, Petri B et al. Delivery of amphotericin B nanosuspensions to the brain and determination of activity against Balamuthia mandrillaris amebas. Nanomedicine 2010; 6: 597-603.
-
(2010)
Nanomedicine
, vol.6
, pp. 597-603
-
-
Lemke, A.1
Kiderlen, A.F.2
Petri, B.3
-
19
-
-
80053613500
-
Peroral amphotericin B polymer nanoparticles lead to comparable or superior in vivo antifungal activity to that of intravenous Ambisome(R) or Fungizone
-
Italia JL, Sharp A, Carter KC et al. Peroral amphotericin B polymer nanoparticles lead to comparable or superior in vivo antifungal activity to that of intravenous Ambisome(R) or Fungizone. PLoS One 2011; 6: e25744.
-
(2011)
PLoS One
, vol.6
-
-
Italia, J.L.1
Sharp, A.2
Carter, K.C.3
-
20
-
-
80155182415
-
Efficacy of intravenous amphotericin B-polybutylcyanoacrylate nanoparticles against cryptococcal meningitis in mice
-
Xu N, Gu J, Zhu Y et al. Efficacy of intravenous amphotericin B-polybutylcyanoacrylate nanoparticles against cryptococcal meningitis in mice. Int J Nanomedicine 2011; 6: 905-13.
-
(2011)
Int J Nanomedicine
, vol.6
, pp. 905-913
-
-
Xu, N.1
Gu, J.2
Zhu, Y.3
-
21
-
-
84866010671
-
Antibacterial activity of silver bionanocomposites synthesized by chemical reduction route
-
Bin Ahmad M, Lim JJ, Shameli K et al. Antibacterial activity of silver bionanocomposites synthesized by chemical reduction route. Chem Cent J 2012; 6: 101.
-
(2012)
Chem Cent J
, vol.6
, pp. 101
-
-
Bin Ahmad, M.1
Lim, J.J.2
Shameli, K.3
-
22
-
-
80051616272
-
Size-selective silver nanoparticles: future of biomedical devices with enhanced bactericidal properties
-
Dal Lago V, Franca de Oliveira L, de Almeida Goncalves K et al. Size-selective silver nanoparticles: future of biomedical devices with enhanced bactericidal properties. J Mater Chem 2011; 21: 12267-73.
-
(2011)
J Mater Chem
, vol.21
, pp. 12267-73
-
-
Dal Lago, V.1
Franca de Oliveira, L.2
de Almeida Goncalves, K.3
-
24
-
-
0029147517
-
Oropharyngeal candidiasis in immunocompromised children: a randomized, multicenter study of orally administered fluconazole suspension versus nystatin
-
Flynn PM, Cunningham CK, Kerkering Tet al. Oropharyngeal candidiasis in immunocompromised children: a randomized, multicenter study of orally administered fluconazole suspension versus nystatin. The Multicenter Fluconazole Study Group. J Pediatr 1995; 127: 322-8.
-
(1995)
The Multicenter Fluconazole Study Group. J Pediatr
, vol.127
, pp. 322-328
-
-
Flynn, P.M.1
Cunningham, C.K.2
Kerkering, T.3
-
25
-
-
65949123789
-
Novel mucoadhesive extended release tablets for treatment of oral candidosis: 'in vivo' evaluation of the biopharmaceutical performance
-
Llabot JM, Manzo RH, Allemandi DA. Novel mucoadhesive extended release tablets for treatment of oral candidosis: 'in vivo' evaluation of the biopharmaceutical performance. J Pharm Sci 2009; 98: 1871-6.
-
(2009)
J Pharm Sci
, vol.98
, pp. 1871-1876
-
-
Llabot, J.M.1
Manzo, R.H.2
Allemandi, D.A.3
-
27
-
-
84865359224
-
Development and characterization of a novel nystatin-loaded nanoemulsion for the buccal treatment of candidosis: Ultrastructural effects and release studies
-
Campos FF, Calpena Campmany AC, Delgado GR et al. Development and characterization of a novel nystatin-loaded nanoemulsion for the buccal treatment of candidosis: Ultrastructural effects and release studies. J Pharm Sci 2012; 101: 3739-52.
-
(2012)
J Pharm Sci
, vol.101
, pp. 3739-3752
-
-
Campos, F.F.1
Calpena Campmany, A.C.2
Delgado, G.R.3
-
28
-
-
0033802638
-
In vitro pharmacodynamic characteristics of nystatin including time-kill and postantifungal effect
-
Gunderson SM, Hoffman H, Ernst EJ et al. In vitro pharmacodynamic characteristics of nystatin including time-kill and postantifungal effect. Antimicrob Agents Chemother 2000; 44: 2887-90.
-
(2000)
Antimicrob Agents Chemother
, vol.44
, pp. 2887-2890
-
-
Gunderson, S.M.1
Hoffman, H.2
Ernst, E.J.3
-
31
-
-
0025315944
-
Experimental oral candidosis in the mouse: microbiologic and histologic aspects
-
Lacasse M, Fortier C, Trudel L et al. Experimental oral candidosis in the mouse: microbiologic and histologic aspects. J Oral Pathol Med 1990; 19: 136-41.
-
(1990)
J Oral Pathol Med
, vol.19
, pp. 136-141
-
-
Lacasse, M.1
Fortier, C.2
Trudel, L.3
-
32
-
-
0033490423
-
High-performance liquid chromatographic determination of liposomal nystatin in plasma and tissues for pharmacokinetic and tissue distribution studies
-
Groll AH, Mickiene D, Werner K et al. High-performance liquid chromatographic determination of liposomal nystatin in plasma and tissues for pharmacokinetic and tissue distribution studies. J Chromatogr B Biomed Sci Appl 1999; 735: 51-62.
-
(1999)
J Chromatogr B Biomed Sci Appl
, vol.735
, pp. 51-62
-
-
Groll, A.H.1
Mickiene, D.2
Werner, K.3
-
33
-
-
84858129679
-
Mouse model of oropharyngeal candidiasis
-
Solis NV, Filler SG. Mouse model of oropharyngeal candidiasis. Nat Protoc 2012; 7: 637-42.
-
(2012)
Nat Protoc
, vol.7
, pp. 637-642
-
-
Solis, N.V.1
Filler, S.G.2
-
34
-
-
62549159532
-
Oral mucosal cell response to Candida albicans in transgenic mice expressing HIV-1
-
de Repentigny L, Lewandowski D, Aumont F et al. Oral mucosal cell response to Candida albicans in transgenic mice expressing HIV-1. Methods Mol Biol 2009; 470: 359-68.
-
(2009)
Methods Mol Biol
, vol.470
, pp. 359-368
-
-
de Repentigny, L.1
Lewandowski, D.2
Aumont, F.3
-
35
-
-
41949100244
-
Drug nanoparticles: formulating poorly water-soluble compounds
-
Merisko-Liversidge EM, Liversidge GG. Drug nanoparticles: formulating poorly water-soluble compounds. Toxicol Pathol 2008; 36: 43-8.
-
(2008)
Toxicol Pathol
, vol.36
, pp. 43-48
-
-
Merisko-Liversidge, E.M.1
Liversidge, G.G.2
-
39
-
-
84857799575
-
Treatment with probiotics in experimental oral colonization by Candida albicans in murine model (DBA/2)
-
Matsubara VH, Silva EG, Paula CR et al. Treatment with probiotics in experimental oral colonization by Candida albicans in murine model (DBA/2). Oral Dis 2012; 18: 260-4.
-
(2012)
Oral Dis
, vol.18
, pp. 260-264
-
-
Matsubara, V.H.1
Silva, E.G.2
Paula, C.R.3
-
40
-
-
0345269817
-
Role of complement C5 and T lymphocytes in pathogenesis of disseminated and mucosal candidiasis in susceptible DBA/2 mice
-
Ashman RB, Papadimitriou JM, Fulurija A et al. Role of complement C5 and T lymphocytes in pathogenesis of disseminated and mucosal candidiasis in susceptible DBA/2 mice. Microb Pathog 2003; 34: 103-13.
-
(2003)
Microb Pathog
, vol.34
, pp. 103-113
-
-
Ashman, R.B.1
Papadimitriou, J.M.2
Fulurija, A.3
-
41
-
-
0028406619
-
Differential pattern of infection and immune response during experimental oral candidiasis in BALB/c and DBA/2 (H-2d) mice
-
Chakir J, Cote L, Coulombe C et al. Differential pattern of infection and immune response during experimental oral candidiasis in BALB/c and DBA/2 (H-2d) mice. Oral Microbiol Immunol 1994; 9: 88-94.
-
(1994)
Oral Microbiol Immunol
, vol.9
, pp. 88-94
-
-
Chakir, J.1
Cote, L.2
Coulombe, C.3
-
42
-
-
79955450697
-
Genetic control of susceptibility to infection with Candida albicans in mice
-
Radovanovic I, Mullick A, Gros P. Genetic control of susceptibility to infection with Candida albicans in mice. PLoS One 2011; 6: e18957.
-
(2011)
PLoS One
, vol.6
-
-
Radovanovic, I.1
Mullick, A.2
Gros, P.3
-
43
-
-
0037090333
-
Mucosal candidiasis in transgenic mice expressing human immunodeficiency virus type 1
-
de Repentigny L, Aumont F, Ripeau JS et al. Mucosal candidiasis in transgenic mice expressing human immunodeficiency virus type 1. J Infect Dis 2002; 185: 1103-14.
-
(2002)
J Infect Dis
, vol.185
, pp. 1103-1114
-
-
de Repentigny, L.1
Aumont, F.2
Ripeau, J.S.3
|